These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35906394)

  • 1. Human antibodies to SARS-CoV-2 with a recurring YYDRxG motif retain binding and neutralization to variants of concern including Omicron.
    Liu H; Kaku CI; Song G; Yuan M; Andrabi R; Burton DR; Walker LM; Wilson IA
    Commun Biol; 2022 Jul; 5(1):766. PubMed ID: 35906394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
    Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
    mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer.
    Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L
    J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SARS-CoV-2 Omicron variant emerged under immune selection.
    Tan CW; Chia WN; Zhu F; Young BE; Chantasrisawad N; Hwa SH; Yeoh AY; Lim BL; Yap WC; Pada SKMS; Tan SY; Jantarabenjakul W; Toh LK; Chen S; Zhang J; Mah YY; Chen VC; Chen MI; Wacharapluesadee S; Sigal A; Putcharoen O; Lye DC; Wang LF
    Nat Microbiol; 2022 Nov; 7(11):1756-1761. PubMed ID: 36195753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron.
    Maeda R; Fujita J; Konishi Y; Kazuma Y; Yamazaki H; Anzai I; Watanabe T; Yamaguchi K; Kasai K; Nagata K; Yamaoka Y; Miyakawa K; Ryo A; Shirakawa K; Sato K; Makino F; Matsuura Y; Inoue T; Imura A; Namba K; Takaori-Kondo A
    Commun Biol; 2022 Jul; 5(1):669. PubMed ID: 35794202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
    Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
    Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies.
    Cao Y; Wang J; Jian F; Xiao T; Song W; Yisimayi A; Huang W; Li Q; Wang P; An R; Wang J; Wang Y; Niu X; Yang S; Liang H; Sun H; Li T; Yu Y; Cui Q; Liu S; Yang X; Du S; Zhang Z; Hao X; Shao F; Jin R; Wang X; Xiao J; Wang Y; Xie XS
    Nature; 2022 Feb; 602(7898):657-663. PubMed ID: 35016194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-reactivity of eight SARS-CoV-2 variants rationally predicts immunogenicity clustering in sarbecoviruses.
    Li Q; Zhang L; Liang Z; Wang N; Liu S; Li T; Yu Y; Cui Q; Wu X; Nie J; Wu J; Cui Z; Lu Q; Wang X; Huang W; Wang Y
    Signal Transduct Target Ther; 2022 Jul; 7(1):256. PubMed ID: 35896529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced Sensitivity of Commercial Spike-Specific Antibody Assays after Primary Infection with the SARS-CoV-2 Omicron Variant.
    Springer DN; Perkmann T; Jani CM; Mucher P; Prüger K; Marculescu R; Reuberger E; Camp JV; Graninger M; Borsodi C; Deutsch J; Lammel O; Aberle SW; Puchhammer-Stöckl E; Haslacher H; Höltl E; Aberle JH; Stiasny K; Weseslindtner L
    Microbiol Spectr; 2022 Oct; 10(5):e0212922. PubMed ID: 36005839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omicron variant receptor-binding domain phylogenetics and molecular dynamics.
    Kandeel M; El-Deeb W
    Comput Biol Med; 2022 Jul; 146():105633. PubMed ID: 35605487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational design of a neutralizing antibody with picomolar binding affinity for all concerning SARS-CoV-2 variants.
    Jeong BS; Cha JS; Hwang I; Kim U; Adolf-Bryfogle J; Coventry B; Cho HS; Kim KD; Oh BH
    MAbs; 2022; 14(1):2021601. PubMed ID: 35030983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralizing monoclonal antibodies elicited by mosaic RBD nanoparticles bind conserved sarbecovirus epitopes.
    Fan C; Cohen AA; Park M; Hung AF; Keeffe JR; Gnanapragasam PNP; Lee YE; Gao H; Kakutani LM; Wu Z; Kleanthous H; Malecek KE; Williams JC; Bjorkman PJ
    Immunity; 2022 Dec; 55(12):2419-2435.e10. PubMed ID: 36370711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.
    He Y; Li J; Li W; Lustigman S; Farzan M; Jiang S
    J Immunol; 2006 May; 176(10):6085-92. PubMed ID: 16670317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization.
    Mannar D; Saville JW; Sun Z; Zhu X; Marti MM; Srivastava SS; Berezuk AM; Zhou S; Tuttle KS; Sobolewski MD; Kim A; Treat BR; Da Silva Castanha PM; Jacobs JL; Barratt-Boyes SM; Mellors JW; Dimitrov DS; Li W; Subramaniam S
    Nat Commun; 2022 Aug; 13(1):4696. PubMed ID: 35982054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced antibody responses in fully vaccinated individuals against pan-SARS-CoV-2 variants following Omicron breakthrough infection.
    Jeong HW; Kim SM; Jung MK; Noh JY; Yoo JS; Kim EH; Kim YI; Yu K; Jang SG; Gil J; Casel MA; Rare R; Choi JH; Kim HS; Kim JH; Um J; Kim C; Kim Y; Chin BS; Jung S; Choi JY; Song KH; Kim YD; Park JS; Song JY; Shin EC; Choi YK
    Cell Rep Med; 2022 Oct; 3(10):100764. PubMed ID: 36182684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of cross-reactive monoclonal antibodies against SARS-CoV-1 and SARS-CoV-2: Implication for rational design and development of pan-sarbecovirus vaccines and neutralizing antibodies.
    Li S; Wu J; Jiang W; He H; Zhou Y; Wu W; Gao Y; Xie M; Xia A; He J; Zhang Q; Han Y; Wang N; Zhu G; Wang Q; Zhang Z; Mayer CT; Wang K; Wang X; Wang J; Chen Z; Jiang S; Sun L; Xia R; Wang Q
    J Med Virol; 2023 Feb; 95(2):e28440. PubMed ID: 36573441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for a conserved neutralization epitope on the receptor-binding domain of SARS-CoV-2.
    Huang KA; Chen X; Mohapatra A; Nguyen HTV; Schimanski L; Tan TK; Rijal P; Vester SK; Hills RA; Howarth M; Keeffe JR; Cohen AA; Kakutani LM; Wu YM; Shahed-Al-Mahmud M; Chou YC; Bjorkman PJ; Townsend AR; Ma C
    Nat Commun; 2023 Jan; 14(1):311. PubMed ID: 36658148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Class of Shark-Derived Single-Domain Antibodies can Broadly Neutralize SARS-Related Coronaviruses and the Structural Basis of Neutralization and Omicron Escape.
    Feng B; Chen Z; Sun J; Xu T; Wang Q; Yi H; Niu X; Zhu J; Fan M; Hou R; Shao Y; Huang S; Li C; Hu P; Zheng P; He P; Luo J; Yan Q; Xiong X; Liu J; Zhao J; Chen L
    Small Methods; 2022 Jul; 6(7):e2200387. PubMed ID: 35583124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees.
    Andreano E; Paciello I; Marchese S; Donnici L; Pierleoni G; Piccini G; Manganaro N; Pantano E; Abbiento V; Pileri P; Benincasa L; Giglioli G; Leonardi M; Maes P; De Santi C; Sala C; Montomoli E; De Francesco R; Rappuoli R
    Nat Commun; 2022 Jun; 13(1):3375. PubMed ID: 35697673
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.